Multiple sclerosis is not yet curable, but the gap between “treatable” and “curable” is narrowing faster than at any point in the disease’s history. Modern therapies can stop relapses entirely in many people, and several experimental approaches are targeting what was once considered permanent damage. A 2025 review in the Annals of Neurology went so far as to suggest MS “could be the first chronic autoimmune disease to be cured,” though that milestone hasn’t arrived yet.
What MS Does to the Nervous System
MS is a disease where the immune system mistakenly attacks the protective coating around nerve fibers in the brain and spinal cord. That coating, called myelin, works like insulation on electrical wiring. When it’s stripped away, nerve signals slow down, misfire, or stop altogether. This leads to symptoms that range from numbness and fatigue to vision problems and difficulty walking.
The damage isn’t limited to myelin. Over time, the nerve fibers themselves can be injured, and this is what drives permanent disability. The distinction matters because myelin damage is potentially reversible, while nerve fiber loss, so far, is not. Any future cure would need to address both: stopping the immune attack and repairing what’s already been damaged.
What Today’s Treatments Can Achieve
The current standard of care focuses on disease-modifying therapies that suppress or redirect the immune system to prevent new attacks. The most effective of these reduce relapse rates by 45 to 50 percent or more compared to older treatments, and they can cut new brain lesion activity by 80 percent or higher. For many people, particularly those started on high-efficacy therapy early, this means years with no relapses, no new lesions on MRI, and no measurable increase in disability.
Doctors now track this outcome using a composite measure called NEDA, or “no evidence of disease activity.” NEDA-3 means a patient has had no relapses, no disability progression, and no new or growing lesions on brain imaging. NEDA-4 adds a fourth criterion: the rate of brain volume loss stays within normal limits, no more than 0.4 percent per year. Achieving NEDA doesn’t mean cured. The disease can still simmer at levels too subtle to detect, and most people eventually lose NEDA status over longer follow-up periods. But it represents something close to remission, and it’s a realistic goal with current treatments.
Life Expectancy With MS
A large Finnish registry study found that MS shortens life expectancy by about seven years on average. Women with MS had a median survival of 79 years compared to 84 in the general population. For men, it was roughly 75 years compared to 79. From the time of diagnosis, median survival was over 36 years for women and 31 years for men. These numbers reflect a mix of patients diagnosed across different eras, some before modern therapies existed. People diagnosed today and treated early will likely do better, though long-term data on the newest treatments is still accumulating.
Stem Cell Transplants: The Closest Thing to a Reset
The most aggressive treatment currently available is autologous hematopoietic stem cell transplantation. The procedure essentially wipes out the existing immune system using chemotherapy and rebuilds it from the patient’s own stem cells. The idea is that the new immune system won’t carry the same programming error that caused it to attack myelin in the first place.
A meta-analysis found that 68 percent of MS patients who underwent the procedure achieved NEDA afterward. That’s a striking number, especially for people whose disease was highly active despite conventional therapy. Some patients have remained relapse-free for a decade or more. But the procedure carries real risks, including serious infections during the period when the immune system is suppressed, and it works best in younger patients with relapsing forms of the disease. It’s not widely offered and is typically reserved for aggressive cases that haven’t responded to standard treatments. It’s also not technically a cure: some patients do relapse after transplant, and the procedure doesn’t repair damage that already exists.
Repairing Damaged Myelin
Stopping new attacks is only half the problem. The other half, the one that would move the needle from “managed” to “cured,” is repairing myelin that’s already been destroyed. This is an area of intense research, with multiple drugs now in clinical trials.
The furthest along is clemastine, an old antihistamine that was discovered to stimulate the brain’s myelin-producing cells. An early trial showed it improved nerve signaling speed in patients with chronic optic nerve damage from MS. At least five additional trials are now testing clemastine in different MS populations, with results expected between 2025 and 2027. One trial is combining it with metformin, a diabetes drug, on the theory that the two together may boost myelin repair more than either alone.
Other approaches in trials include a nanocrystalline gold compound that supports the energy metabolism of brain cells, a hormone-modulating drug being tested in postmenopausal women with MS, and a drug that blocks a receptor involved in nerve cell signaling. These are all in phase II trials, meaning they’ve shown enough promise to justify larger studies but haven’t yet proven themselves. Myelin repair remains the most challenging frontier in MS research, and no therapy has yet demonstrated large-scale, clinically meaningful remyelination in humans.
A New Class of Drugs for Progressive MS
The forms of MS that have been hardest to treat are the progressive types, where disability accumulates gradually rather than in distinct relapses. Most existing therapies were designed to prevent relapses and have limited effect on this slow, steady worsening. The underlying biology is different: progressive MS involves chronic, low-grade inflammation driven partly by immune cells residing inside the brain itself, not just those entering from the bloodstream.
A new class of drugs called BTK inhibitors is designed to reach these resident brain immune cells. Several are in phase III trials for both primary progressive MS and secondary progressive MS. Early-phase results have been promising enough to justify these large trials, but definitive efficacy data isn’t available yet. If they work, they would fill a major gap, offering the first treatments that meaningfully slow progression in people whose disease has moved beyond the relapsing phase.
Could MS Be Prevented Entirely?
One of the most compelling developments isn’t about treatment at all. It’s about prevention. A growing body of evidence has established that Epstein-Barr virus, the virus responsible for mononucleosis, is a necessary trigger for MS. Virtually all people who develop MS have been infected with EBV, and having mononucleosis significantly increases the risk.
This has prompted serious discussion about whether an EBV vaccine could prevent MS from developing in the first place. Several EBV vaccines are now in development. The challenge is proving they prevent MS, which could require studies with hundreds of thousands of participants followed for decades, since MS typically develops years after EBV infection. Researchers are exploring faster study designs, including ones that measure whether vaccination prevents mononucleosis as a proxy for MS prevention. This won’t help people who already have MS, but it represents the most plausible path to eventually eliminating the disease.
Earlier Diagnosis Is Changing Outcomes
Updated diagnostic criteria published in 2025 are designed to catch MS earlier and more accurately. The revisions expanded the number of brain and spinal cord regions that count toward a diagnosis from four to five, now including the optic nerve. They also introduced new imaging markers: a “central vein sign” visible inside brain lesions and “paramagnetic rim lesions” that indicate ongoing inflammation, which are over 95 percent specific for MS. A new spinal fluid biomarker was added as an alternative to the traditional test for oligoclonal bands.
Perhaps most significantly, the updated criteria no longer always require proof that the disease has been active at two separate points in time. If spatial involvement is extensive enough, a single evaluation can be sufficient for diagnosis. This matters because the strongest predictor of long-term outcomes in MS is how early treatment begins. Every month of unchecked disease activity allows damage to accumulate. Faster diagnosis means faster treatment, which means a better chance of achieving and maintaining NEDA.
Where Things Stand
MS in 2025 is a disease that can be controlled, often impressively well, but not yet cured. The immune attack can be suppressed to the point of clinical silence in many patients. Damaged myelin cannot yet be reliably repaired, and lost nerve fibers cannot be regrown. The treatments that come closest to a reset, like stem cell transplant, work for a subset of patients and don’t reverse existing damage. The most transformative possibilities, myelin repair drugs, BTK inhibitors for progressive disease, and EBV vaccines for prevention, are all still in clinical trials. For someone diagnosed today, the practical reality is that early, aggressive treatment offers the best chance of living a full life with minimal disability, while the science works toward something more definitive.